Chronic Disease Management

The chronic disease management market encompasses consumers with chronic, complex conditions such as chronic kidney disease, diabetes, and heart disease. The challenges faced in this market are often compounded by the need for social services and supports. For provider organizations and health systems managing consumers with chronic conditions, a significant challenge that remains is addressing the rising cost of care for this population. As a result, payers are focusing on reducing the spend by increasing integrated models of care coordination across medical, behavioural, pharmacy, and social support systems. These new market forces are creating strategic opportunities for provider organizations that are serving this population.

Latest Resources

• Andor Health & Psynergy Health Launch Tech-Enabled Chronic Care Clinic For The Medicare ACCESS Program
• Health Innovation South West & Helfie AI Partner To Evaluate Digital-First Hypertension Screening
• Kidney Transplant Rates Lower For Medicare Advantage Than Traditional Medicare
• Trump Administration Announces $51 Million For Rural Texas Nutrition & Chronic Disease Prevention Programs
• People With I/DD Less Likely To Receive Kidney Transplant Evaluation Or Transplant
• Navitus Launches GLP-1 Pathways & DirectAccess Direct-To-Consumer Option
• Specialty Pharmacy Use For Cancer Treatment Associated With 12% Fewer Hospitalizations & 8% Lower Medical Costs
• Dario To Provide Its Digital Cardiometabolic Management Program With New Jersey Health Plan Representing 1.5 Million Covered Lives
• Ayble Health Raises $16 Million In Series A Funding To Expand Its Virtual Digestive Health Clinic
• Medicare Launches ACCESS Model; Outcome-Based Payments For Technology-Enabled Care Includes Depression, SUD & Nicotine Addiction
• Advancing Chronic Care With Effective, Scalable Solutions (ACCESS) Model Payment Amounts & Performance Targets Effective Period: July 5, 2026 – December 31, 2027
• Half Of Adults Starting Semaglutide For Weight Loss Stop Within A Year
• GLP-1 Use Among Children Ages 8 To 11 With Obesity Is Low But Rising
• FDA Selects Four Digital Health Companies For TEMPO Pilot; Two Focus On Behavioral Health
• GLP-1 Prescribing Lags Among Adults With Schizophrenia & Diabetes

See All

Treating Obesity & Type 2 Diabetes Reduced Kidney Disease By 62%

Participants in a metabolic care program for type 2 diabetes and obesity/overweight had a 36% lower risk of developing chronic kidney disease (CKD) compared to a matched group who received usual care. Participants also had a 43% lower risk of developing CKD stage 3 or higher and a 62% lower risk of developing CKD stage 4 or higher. The study involved the Virta Health Individualized Nutrition Therapy (VINT) program. VINT is a remotely administered metabolic… Read

• GLP-1s Associated With Lower Mortality Among Adults With Serious Mental Illness
• Older Adults Taking 5 Or More Prescription Drugs Had 38% Higher Mortality Risk
• Mend Well Launches Expanded Chronic Condition Management, Extending Surgical Care Into Long-Term Obesity & Hypertension Support
• West Virginia Offers $2 Million To Expand Home Dialysis Access
• Meant Earns LegitScript Certification For Its Online GLP-1 Weight Care Platform

To sign-up for monthly Chronic Disease Management alerts, you must be signed in to your account.